| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2197356 | Molecular and Cellular Endocrinology | 2009 | 8 Pages |
Anti-estrogen therapies for treating ovarian carcinoma have had mixed outcomes suggesting some tumors may be estrogen-dependent. We assayed the activity levels of 17β-hydroxysteroid dehydrogenase (17β-HSD), 3β-hydroxysteroid dehydrogenase (3β-HSD), 3α-hydroxysteroid dehydrogenase (3α-HSD/3-KSR) and estrone sulfatase in a series of ovarian epithelial carcinomas. 17β-HSD activity ratios with estradiol (E2) and testosterone (T), and inhibition by isoform-specific inhibitors were used to estimate the contributions of 17β-HSD isoforms. Activity levels were highest for estrone sulfatase, followed, respectively by 17β-HSD, 3α-HSD/3-KSR, and 3β-HSD. E2/T activity ratios varied widely between samples. A 17β-HSD type 1 inhibition pattern was observed in 23% of the samples and a type 2 pattern in 25%. E2 formation from estrone sulfate (E1S) was detected in 98% (47/48) of the samples. 17β-HSD type 1, type 2 and type 5 mRNA was detected in matched primary tumor and metastases. Evaluation of 17β-HSD and sulfatase activity levels, activity ratios and inhibition patterns may help predict tumor response to endocrine therapy.
